Literature DB >> 1703324

Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist.

S McLean1, A H Ganong, T F Seeger, D K Bryce, K G Pratt, L S Reynolds, C J Siok, J A Lowe, J Heym.   

Abstract

CP-96,345, a nonpeptide substance P antagonist, is selective for the tachykinin NK1 receptor. The compound binds to a single population of sites in guinea pig brain and potently inhibits substance P-induced excitation of locus ceruleus neurons. CP-96,345 should be a useful tool for studying the action of substance P in the central nervous system.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1703324     DOI： 10.1126/science.1703324

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  23 in total

1.  The non-peptide tachykinin antagonist, CP-96,345, is a potent inhibitor of neurogenic inflammation.

Authors:  F Lembeck; J Donnerer; M Tsuchiya; A Nagahisa
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

2.  CP-96,345, a non-peptide antagonist of substance P: I. Effects on the actions mediated by substance P and related tachykinins on the guinea-pig ileum and rabbit jejunum.

Authors:  F J Legat; T Griesbacher; F Lembeck
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

3.  Non-invasive Brain Delivery and Efficacy of BDNF in APP/PS1 Transgenic Mice as a Model of Alzheimer's Disease.

Authors:  Brian M Kopec; Liqin Zhao; Eduardo Rosa-Molinar; Teruna J Siahaan
Journal:  Med Res Arch       Date:  2020-02

4.  Inhibitory action of (+/-)CP-96,345 on the cardiovascular responses to intrathecal substance P and neuropeptide K in the conscious freely moving rat.

Authors:  T M Pham; R Couture
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-01       Impact factor: 3.000

5.  CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.

Authors:  D W Schulz; R S Mansbach; J Sprouse; J P Braselton; J Collins; M Corman; A Dunaiskis; S Faraci; A W Schmidt; T Seeger; P Seymour; F D Tingley; E N Winston; Y L Chen; J Heym
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

6.  Substance P-mediated slow excitatory postsynaptic potential elicited in dorsal horn neurons in vivo by noxious stimulation.

Authors:  Y De Koninck; J L Henry
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

Review 7.  Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.

Authors:  Erika Pintér; Gábor Pozsgai; Zsófia Hajna; Zsuzsanna Helyes; János Szolcsányi
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

8.  Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists.

Authors:  J C Beaujouan; E Heuillet; F Petitet; M Saffroy; Y Torrens; J Glowinski
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

9.  Block of voltage-dependent sodium currents by the substance P receptor antagonist (+/-)-CP-96,345 in neurones cultured from rat cortex.

Authors:  M Caeser; G R Seabrook; J A Kemp
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

10.  Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat.

Authors:  C Tschöpe; P Picard; J Culman; A Prat; K Itoi; D Regoli; T Unger; R Couture
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.